Moderna, BioNTech rise as vaccine advisory panel backs off mRNA vaccine threat
Source: SeekingAlpha
2026-03-11 15:24:26 ET
More on Moderna, BioNTech
- BioNTech SE 2025 Q4 - Results - Earnings Call Presentation
- BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
- Moderna: Pipeline Hope Won't Pay The Bills
- Biontech outlines €2B–€2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition
- BioNTech falls on outlook, departure of co-founders
Read the full article on Seeking Alpha
For further details see:
Moderna, BioNTech rise as vaccine advisory panel backs off mRNA vaccine threat
Pfizer Inc.
NASDAQ: PFE
PFE Trading
-0.87% G/L:
$26.7599 Last:
15,428,140 Volume:
$27.03 Open:
PFE Latest News
March 23, 2026 06:45:00 am
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
March 20, 2026 04:30:00 pm
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC
PFE Stock Data
$156,612,814,520
5,628,850,476
0.02%
1712
N/A
Pharmaceuticals
Healthcare
US
New York
